SCPC provides comments on the Part D provisions of the 2023 CMS Call Letter
Dear Director Seshamani:
The Senior Care Pharmacy Coalition (SCPC) appreciates the opportunity to comment on the Part D provisions of the 2023 CMS Call Letter entitled, “Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies” (the “Call Letter” or the “Proposal”), CMS 2022-0021. SCPC is the only Washington-based organization exclusively representing the interests of long-term care (LTC) pharmacies. SCPC’s membership includes 80% of all independent LTC pharmacies and our members serve one million residents daily in skilled nursing facilities and assisted living communities across the country.1 Given the distinct characteristics of the LTC patient population and the enhanced clinical responsibilities of LTC pharmacies, we offer unique perspectives on CMS’ initiatives and proposals, and particularly how Medicare Prescription Drug Benefit (“Part D”) policies and requirements impact the pharmacy community.
In brief, our comments address CMS’ proposed use pharmacy quality metrics to evaluate Medicare Prescription Drug Plans (PDPs). PDPs are insurance companies not pharmacies, and their performance should be evaluated using criteria relevant to the manner in which Part D beneficiaries evaluate insurance companies providing drug coverage, not pharmacies providing prescription drugs and related services. Our comments also address CMS’ proposed use of Pharmacy Quality Alliance (PQA) pharmacy quality measures as a component of the Star Rating metrics without appropriate qualification and without metrics specific to the LTC patient population. We are concerned that the use of PQA Measures inadvertently could skew evaluation of LTC pharmacy quality, unintentionally mislead LTC patients in selecting a LTC pharmacy and unjustifiably empower Part D Plans (PDPs) and the pharmacy benefit managers (PBMs) that administer PDPs to penalize LTC pharmacies based on inaccurate quality assessments. We also are concerned that use of the proposed opioid utilization measures in determining Star Ratings for PDPs risks undermining the quality of care for LTC patients because those measures are inappropriate to the LTC patient population due to substantially different clinical needs.
Click here to read the full letter.
Recent Posts
-
Bring it on home: Obstacles and opportunities in bringing long-term care pharmacy services to Medicare beneficiaries living at home
By Alan Rosenbloom As anyone who has been prescribed medication knows, pharmacies play a crucial role in our health care system. This is especially true for older people, since their reliance on medications to treat their overall health care needs increases. While younger, healthier people can turn to a local retail pharmacist, people with medically […]
-
Free market is at risk because of PBM titans’ anti-competitive behaviors
Congress must thoroughly investigate the anti-competitive behaviors of these conglomerates and act accordingly. Doing so will provide better outcomes both for patients and a more competitive marketplace for unaffiliated pharmacies. By Alan Rosenbloom We’ve been here before, right? A Congress and Administration eager to talk about mysterious escalating prescription drug prices. Over the years, both […]
-
Health Equity and Access to LTC Pharmacy Services
Limited community access to LTC pharmacy services has implications for achieving health equity in LTC. The confluence of needs for long-term care and chronic health care services among Medicare beneficiaries who need LTC should be central to policy making. Congress and CMS should craft integrated policies that address chronic health care and LTC needs for individuals living in the community, and medication management should be central to such efforts.
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.